<DOC>
	<DOCNO>NCT01903954</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety setrobuvir patient genotype 1 chronic hepatitis C. Treatment-naïve patient randomize receive either setrobuvir ( 800 mg orally b.i.d load dose follow 200 mg orally .b.i.d . ) placebo combination standard care Pegasys ( peginterferon alfa-2a ) Copegus ( ribavirin ) . Treatment duration 28 week 48 week depend response . Treatment-experienced patient categorized relapsers , partial responder viral breakthrough patient previous pegylated interferon ribavirin therapy randomize receive either setrobuvir placebo combination Pegasys Copegus 48 week . Treatment-experienced patient categorize null-responders previous pegylated interferon ribavirin therapy assign treatment setrobuvir plus Pegasys Copegus 48 week .</brief_summary>
	<brief_title>A Study Setrobuvir Combination With Pegasys ( Peginterferon Alfa-2a ) Copegus ( Ribavirin ) Patients With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , 18 65 year age inclusive Documented chronic hepatitis C Treatmentnaïve ( prior exposure Pegasys , Copegus , experimental HCV therapy ) treatmentexperienced current standard care ( Pegasys Copegus ) categorize nullresponder patient partial response , relapse viral breakthrough follow prior treatment Serum HCV RNA &gt; /= 50,000 IU/mL screen HCV antibody positive screening HCV genotype 1 Body mass index ( BMI ) 1838 kg/m2 In good health chronic HCV infection judgment principal investigator Negative hepatitis B HIV infection Pregnant breastfeeding woman For treatmentnaïve patient : previous treatment HCV infection For treatmentexperienced patient : previous treatment experimental therapy HCV infection Coinfection HIV hepatitis C virus ( HBV ) History evidence decompensated liver disease History evidence hepatocellular carcinoma History alcohol abuse and/or drug addiction &lt; /= 1 year prior enrollment study Poorly control diabetes mellitus One additional know primary cause liver disease hepatitis C History acute chronic pancreatitis Participation clinical study new chemical entity within 30 day prior study randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>